Home > Products > Intermediates > Febuxostat Intermediates > Febuxostat Intermediate Cas 161798-03-4 Classification

Febuxostat Intermediate Cas 161798-03-4 Classification

    Payment Type: L/C,T/T,D/P
    Incoterm: FOB,CFR,CIF,EXW,FCA
    Min. Order: 5 Gram
    Delivery Time: 2 Days
Basic Info

Model No.: Jianfeng

Shelf Life: 3 Years

Form: Powder Form

Purity: 99%

Storage: Cool

Description: WHITE

Grade Standard: Medicine Grade

Other Name: 2-(3-forMyl

Type: Auxiliaries And Other Medicinal Chemical

EINECS: 700-743-4

Molecular Weight: 347.43

Additional Info

Packaging: Drum

Productivity: 2000kg

Brand: Jianfeng

Transportation: Ocean,Land,Air

Place of Origin: China

Supply Ability: 2000kg

Certificate: ISO

HS Code: 29349990.99

Port: Qingdao,Shanghai,Tianjin

Product Description
Febuxostat, a selective xanthine oxidase inhibitor, was launched for the chronic management of hyperuricemia in patients with gout. Hyperuricemia is defined as a serum uric acid concentration exceeding the limit of solubility. It predisposes affected persons to gout, a disease characterized by the formation of crystals of monosodium urate or uric acid from supersaturated fluids in joints and other tissues. Crystal deposition is asymptomatic, but it is revealed by bouts of joint inflammation. If left untreated, further crystals accumulate in joints and can form deposits known as tophi. A major aim in gout management is the long-term reduction of serum uric acid concentrations below saturation levels, as this results in crystal dissolution and eventual disappearance.
Febuxostat is a nonpurine derivative with higher potency and selectivity than allopurinol for inhibiting xanthine oxidase. It completely inhibits human xanthine oxidase activity in the lung cancer cell line A549, whereas the activities of other enzymes involved in purine or pyrimidine metabolism (e.g., purine nucleoside phosphorylase, adenosine deaminase, and pyrimidine nucleoside phosphorylase) are affected by <4%.
The incidence of adverse events such as dizziness, diarrhea, headache, and nausea with febuxostat was similar to allopurinol. Febuxostat is contraindicated in patients being treated with the xanthine oxidase substrates such as azathioprine, mercaptopurine, and theophylline. Febuxostat can be synthesized in a multistep sequence from 2,4-dicyanophenol, starting with the alkylation of the phenolic hydroxyl group with isobutyl bromide and potassium carbonate, followed by treatment with thioacetamide in hot dimethyl formamide to yield 3-cyano-4-isobutoxythiobenzamide. Cyclization of the thioamide group with 2-chloroacetoacetic acid ethyl ester in refluxing ethanol affords 2-(3-cyano-4-isoutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester, which is hydrolyzed with sodium hydroxide to produce febuxostat.

161798 03 4

The other name of the product is Package Febuxostat Intermediate,Cas 161798-03-4 Classification,Uses Cas 161798-03-4.

Looking for ideal Package Febuxostat Intermediate Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the Cas 161798-03-4 Classification are quality guaranteed. We are China Origin Factory of Uses Cas 161798-03-4. If you have any question, please feel free to contact us.

Product Categories : Intermediates > Febuxostat Intermediates

Email to this supplier
  • *Subject:
  • *Messages:
    Your message must be between 20-8000 characters
Communicate with Supplier?Supplier
Mr. Vid Mr. Mr. Vid
What can I do for you?
Contact Supplier